← All trials
NCT05253846
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 25, 2022
- Primary completion
- May 30, 2024
- Completion date
- Oct 30, 2028
- First posted
- Feb 24, 2022
- Last posted
- Mar 10, 2022
- Enrollment
- 63
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Gruppo Oncologico del Nord-OvestLead sponsor
- University of PisaOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.